Revere Pharma has developed an innovative drug discovery and development platform that drives our small molecule pipeline targeting Rac1 and its genomic variants.
Customized assays for evaluating Rho GTPase inhibitors
We have customized biochemical, cellular and phenotypic assays for Rac1, other Rho GTPases and their genomic variants. These proprietary assays enable us to identify drug candidates for select patients whose cancers are defined by the aberration of specific Rho GTPases.
We have a unique high-throughput platform that rapidly assesses inhibitory activity of tens of thousands of compounds.
Structure-based Drug Design
We have identified allosteric binding pockets on Rho GTPase proteins to aid in structure-based drug design and guide medicinal chemistry optimization of hits from our high throughput screening.